Abbvie (ABBV) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AbbVie (ABBV) has completed a Phase 1a study titled “A Phase 1a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses of ABBV-142 in Healthy Adult Subjects and Single Doses of ABBV-142 in Healthy Adult Asian Subjects.” The goal was to see how ABBV-142 moves through the body, how safe it is at rising doses, and whether it triggers immune reactions, helping AbbVie judge if the drug can advance into studies in patients.
The study tested ABBV-142, an experimental drug given as either an intravenous infusion or a subcutaneous injection. It was compared with matched placebo injections and infusions to spot true drug effects and to guide future dosing and route decisions in later trials.
The trial used a randomized, placebo-controlled design with several groups getting different single doses in sequence. It was quadruple-blinded, meaning participants, doctors, study staff, and outcome assessors did not know who received ABBV-142 or placebo, and the main aim was basic research on safety and drug handling in the body.
AbbVie first submitted the study on 2025-01-09, marking its formal entry into the clinical pipeline. The trial is listed as completed, and the record was last updated on 2026-05-04, signaling that AbbVie has finished dosing and follow-up and is now likely analyzing the data for internal go or no-go decisions.
For investors, completion of this early-stage study reduces some development risk around ABBV-142 and supports AbbVie’s broader pipeline story, even though no results are posted yet. The update may modestly improve sentiment toward ABBV if investors expect a new immunology or oncology asset, while peers like Amgen and Johnson & Johnson also push early biologics, keeping competitive pressure high.
The ABBV-142 trial is completed and recently updated, and further details are available on the ClinicalTrials.gov portal under identifier NCT06774313.
To learn more about ABBV’s potential, visit the Abbvie drug pipeline page.